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Abstract 
Background: We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) out-
comes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on 
ppOS.
Methods: Recursive partitioning analysis (RPA) was performed to model relationships between prespecified covari-
ates and ppOS in patients with BRAFV600-mutated metastatic melanoma who had experienced progressive disease 
(PD) following treatment with cobimetinib plus vemurafenib, vemurafenib monotherapy, or dacarbazine in the  
BRIM-2, BRIM-3, BRIM-7, and coBRIM studies. Prognostic subgroups identified by RPA were then applied to pooled 
treatment cohorts. The primary endpoint was ppOS, defined as time from first PD to death from any cause.
Results: RPA identified baseline lactate dehydrogenase (LDH), baseline disease stage, Eastern Cooperative Oncol-
ogy Group performance status at PD, and ppRx as significant prognostic factors for ppOS. Median ppOS was longest 
in patients with normal baseline LDH, stage M1c disease at baseline, and ppRx with immunotherapy or targeted 
therapy (12.2 months; 95% CI 10.3–16.1) and shortest in those with elevated baseline LDH > 2 × upper limit of normal 
(2.3 months; 95% CI 1.8–2.7). Original treatment assignment did not impact ppOS. Across treatment cohorts, patients 
treated with immunotherapy or targeted therapy after PD had better ppOS than those given other treatments.
Conclusion: A combination of factors at baseline (LDH, disease stage) and PD (performance status, ppRx) impact 
ppOS outcomes. ppRx with immunotherapy or targeted therapy is an independent prognostic factor for improved 
overall survival following progression regardless of original treatment.
Trial registration The trials included in this analysis are registered with ClinicalTrials.gov: NCT00949702 (BRIM-2), 
NCT01006980 (BRIM-3), NCT01271803 (BRIM-7), and NCT01689519 (coBRIM).
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Background
Vemurafenib monotherapy and cobimetinib plus 
vemurafenib have improved survival in patients with 
BRAFV600-mutated metastatic melanoma [1–7]. 
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Extended follow-up of clinical studies evaluating BRAF 
inhibitor (BRAFi) monotherapy or combined BRAFi and 
MEK inhibitor (MEKi) shows a plateau in overall sur-
vival (OS) curves after approximately 3  years [8–11]. A 
similar plateau in OS is observed with ipilimumab [12]. 
These observations suggest that a subgroup of patients 
with metastatic melanoma have good long-term survival 
prognosis. Prognostic factors for survival in patients 
with metastatic melanoma include disease stage (num-
ber/location of metastases), baseline lactate dehydroge-
nase (LDH), and baseline Eastern Cooperative Oncology 
Group performance status (ECOG PS) [13, 14]. Recent 
analyses suggest that LDH remains the most important 
prognostic factor for survival in patients treated with 
BRAFi and/or MEKi or immunotherapy, with particu-
larly poor outcomes being observed in patients with 
LDH elevated > 2 × upper limit of normal (ULN) [15–18]. 
However, the impact on survival outcomes of clinical 
and disease-related variables and treatment following 
progression are poorly understood. Some reports sug-
gest that prior BRAFi treatment is associated with infe-
rior response to subsequent immunotherapy [19–23], 
whereas others suggest that the efficacy of immunother-
apy is unaffected by previous BRAFi therapy [24–27]. 
Insight into the impact of clinical characteristics and 
subsequent treatment on survival following progressive 
disease (PD) may inform treatment decisions in the man-
agement of patients with metastatic melanoma.
The objectives of this analysis were to 1) identify 
patient subgroups with distinct postprogression overall 
survival (ppOS) outcomes and 2) investigate the impact 
of original assigned treatment (cobimetinib plus vemu-
rafenib, vemurafenib monotherapy, or dacarbazine) and 
initial postprogression treatment (ppRx) on ppOS in 
patients with BRAFV600-mutated metastatic melanoma.
Methods
Study design and participants
Data were pooled from the BRIM-2 (NCT00949702) [1], 
BRIM-3 (NCT01006980) [3, 4], BRIM-7 (NCT01271803) 
[5], and coBRIM (NCT01689519) [6, 7] studies. Detailed 
methods have been previously reported. Briefly, BRIM-2 
was an open-label, multicenter phase 2 trial of oral 
vemurafenib 960  mg twice daily [2]. BRIM-3 was an 
open-label, multicenter, randomized phase 3 trial of oral 
vemurafenib 960  mg twice daily compared with intra-
venous dacarbazine 1000  mg/m2 every 3  weeks [3, 4]. 
BRIM-7 was an open-label, multicenter phase 1b dose-
escalation study of oral cobimetinib 60, 80, or 100  mg 
once daily on a 14 days on/14 days off schedule (14/14), 
a 21 days on/7 days off schedule (21/7), or continuously 
(28/0) combined with oral vemurafenib 720 or 960  mg 
twice daily [5]. coBRIM was a randomized, double-blind 
phase 3 study of the combination of oral cobimetinib 
60 mg once daily on a 21/7 schedule combined with oral 
vemurafenib 960 mg twice daily compared with placebo 
plus vemurafenib [6, 7]. Key eligibility criteria were simi-
lar across trials; eligible patients were aged ≥ 18  years 
with unresectable stage IIIC or IV melanoma harboring 
a BRAFV600 mutation, ECOG PS of 0–1, and adequate 
organ function. BRIM-3 and coBRIM enrolled previ-
ously untreated patients only, whereas BRIM-2 enrolled 
patients who had received prior systemic treatment for 
advanced disease, and BRIM-7 enrolled both previously 
treated and untreated patients. All four trials allowed 
enrollment of patients with previously treated, stable 
brain metastases.
All eligible patients (defined by each study protocol) 
who had PD at the time of data cutoff were included in 
analyses regardless of treatment assignment. Patients 
with missing data for covariates of interest were excluded. 
For BRIM-7, only BRAFi-naive patients were included in 
the analysis.
Statistical analysis
Recursive partitioning analysis
Recursive partitioning analysis (RPA) is a statistical 
method that creates a decision tree by classifying patients 
into subgroups, defined by independent prognostic fac-
tors, with statistically distinct survival probabilities. RPA 
was undertaken to model relationships between prespec-
ified covariates and ppOS in patients who had experi-
enced PD at the time of data cutoff (BRIM-2: February 1, 
2012; BRIM-3: July 8, 2015; BRIM-7: December 2, 2015; 
coBRIM: August 28, 2015).
Covariates were prespecified in study protocols and/
or identified as potential prognostic factors from peer-
reviewed medical literature. Prespecified baseline covari-
ates were age (< 65 vs ≥ 65  years), sex (male vs female), 
race (white vs nonwhite), geographic region (North 
America, Europe, or Australia/New Zealand/other), 
ECOG PS (0, 1, or 2), disease stage (unresectable IIIC, 
M1a, M1b, M1c), LDH (normal, elevated ≤ 2 × ULN or 
elevated > 2 × ULN), sum of longest diameters (SLD) of 
target lesions, histologic subtype (acral lentiginous, len-
tigo maligna, nodular, superficial spreading, or other), 
prior adjuvant therapy (yes vs no), and original treatment 
assignment (cobimetinib plus vemurafenib, vemurafenib 
monotherapy, or dacarbazine). Prespecified covariates 
at the time of PD were best response before PD, LDH 
(normal, elevated ≤ 2 × ULN, or elevated > 2 × ULN), 
ECOG PS (0, 1, or 2), metastasis (new lesion vs no new 
lesion; central nervous system [CNS] vs non-CNS), SLD, 
enlargement of baseline lesions, maximum change in 
SLD, time from maximum change in SLD to PD, abso-
lute lymphocyte count (normal, low, or elevated), ratio of 
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absolute neutrophil count to absolute lymphocyte count, 
and initial ppRx (immunotherapy/targeted therapy vs 
other).
Initial ppRx was defined as ≥ 1 dose of ipilimumab, 
pembrolizumab, nivolumab, or similar therapy within 
90  days after PD (immunotherapy); ≥ 1 dose of vemu-
rafenib, cobimetinib, dabrafenib, trametinib, or similar 
therapy within 90  days after PD (targeted therapy); or 
receipt of any therapy other than immunotherapy or tar-
geted therapy, both immunotherapy and targeted ther-
apy, or no treatment within 90 days after PD (other).
RPAs used a unified framework for conditional infer-
ence (permutation tests) using censored response varia-
bles to avoid bias in selection of covariates and minimize 
overfitting of the data [28]. This approach ensures a right-
sized tree with no need for pruning or cross-validation. 
The global null hypothesis of independence between 
any of the prespecified input variables and survival was 
tested. If the null hypothesis could not be rejected, the 
analysis was stopped; otherwise, the covariate most 
strongly associated with survival was identified based on 
univariate P values and a binary split was implemented. 
These steps were repeated until no further covariates 
with a significant association with survival could be dis-
tinguished. The stop criterion was based on either mul-
tiplicity-adjusted univariate P values or a prespecified 
threshold value of the test statistic (both criteria were 
maximized using 1—P value).
ppOS
The primary endpoint for this analysis was ppOS, defined 
as time from first PD to death from any cause, estimated 
using the Kaplan–Meier method. ppOS was evaluated 
using updated data in patients who had experienced 
PD at the time of updated data cutoff (BRIM-2: Febru-
ary 1, 2012; BRIM-3: July 8, 2015; BRIM-7: July 10, 2017; 
coBRIM: October 13, 2017). Prognostic subgroups iden-
tified by RPA were applied to the total pooled population 
and to pooled treatment cohorts (cobimetinib plus vemu-
rafenib, vemurafenib monotherapy, and dacarbazine). 
Patients who did not die were censored at data cutoff.
Results
RPA
At the time of data cutoff for the RPA, 1004 patients 
had experienced PD; after excluding patients with miss-
ing data, 809 patients were included in the RPA. Demo-
graphic and clinical characteristics were comparable 
across the pooled population and pooled treatment 
cohorts (Table 1).
Median postprogression follow-up durations were 
5.4 months (interquartile range [IQR], 2.2–12.5 months) 
for all patients, 4.8  months (IQR, 1.9–10.7  months) for 
the cobimetinib plus vemurafenib cohort, 5.2  months 
(IQR, 2.2–12.0  months) for the vemurafenib monother-
apy cohort, and 6.5  months (IQR, 2.6–15.6  months) for 
the dacarbazine cohort.
In all pooled patients, the RPA identified baseline LDH, 
baseline disease stage, ECOG PS at PD, and initial ppRx 
as significant prognostic factors for ppOS, producing 
seven subgroups with distinct outcomes (Fig. 1). Notably, 
CNS metastasis at PD was not identified as a significant 
prognostic factor for ppOS, although this subgroup was 
relatively small (n = 174). Baseline LDH level was the 
strongest determinant of ppOS. Baseline disease stage 
(IIIC/M1a/M1b vs M1c) was identified as a significant 
prognostic factor among patients with normal baseline 
LDH but not among those with elevated LDH. Initial 
ppRx (immune/targeted therapy vs other) was a signifi-
cant prognostic factor among patients with normal base-
line LDH and baseline disease stage M1c, and among 
those with baseline LDH elevations ≤ 2 × ULN. ECOG 
PS at the time of PD was prognostic for ppOS among 
patients with normal baseline LDH, baseline disease 
stage M1c, and initial ppRx other than immune/targeted 
therapy. After adjusting for other covariates, including 
original treatment assignment, initial ppRx with immu-
notherapy or targeted therapy was associated with longer 
ppOS than other ppRx. Original treatment assignment 
(cobimetinib plus vemurafenib, vemurafenib monother-
apy, or dacarbazine) was not identified as a prognostic 
factor for ppOS.
ppOS
At the time of updated data cutoff for ppOS, 1027 
patients had experienced PD; after excluding patients 
with missing data, 955 patients were included in analy-
ses of ppOS based on RPA-defined prognostic subgroups. 
Demographic and clinical characteristics remained com-
parable across cohorts (Additional file 1: Table S1).
Median postprogression follow-up durations were 
5.5  months (IQR, 2.2–14.0  months) for all patients, 
5.2  months (IQR, 2.1–14.0  months) for the cobimetinib 
plus vemurafenib cohort, 5.3  months (IQR, 2.2–
13.2  months) for the vemurafenib monotherapy cohort, 
and 6.5  months (IQR, 2.6–15.6  months) for the dacar-
bazine cohort.
Among all patients, median ppOS was longest in the 
subgroup with normal baseline LDH, baseline disease 
stage M1c, and initial ppRx with immunotherapy or 
targeted therapy (12.2  months; 95% CI 10.3–16.1) and 
shortest in those with elevated baseline LDH > 2 × ULN 
(2.3  months; 95% CI 1.8–2.7). Application of prog-
nostic factors identified in the RPA across treatment 
cohorts (cobimetinib plus vemurafenib, vemurafenib 
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monotherapy, and dacarbazine) revealed similar trends 
in ppOS (Fig. 2).
ppOS outcomes, stratified by prognostic subgroups 
identified in the RPA, appeared to be similar across 
treatment cohorts (Table  2), consistent with the ini-
tial RPA demonstrating no impact of original treatment 
assignment on ppOS. Among patients with normal base-
line LDH, baseline disease stage M1c, and initial ppRx 
with immunotherapy or targeted therapy (the most 
favorable subgroup), 3-year ppOS rates were 21.7% 
(95% CI 0.0–44.2) in the cobimetinib plus vemurafenib 
cohort, 22.3% (95% CI 10.3–34.3) in the vemurafenib 
Table 1 Demographic and clinical characteristics for patients included in the RPA
ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, PD progressive disease, ppOS postprogression overall survival, RPA 
recursive partitioning analysis, SLD sum of longest diameters, ULN upper limit of normal
Characteristic All pooled patients 
N = 1004
Cobimetinib + vemurafenib 
n = 184
Vemurafenib 
monotherapy n = 555
Dacarbazine n = 265
Age, n (%) (n = 1004) (n = 184) (n = 555) (n = 265)
 < 65 y 758 (75.5) 142 (77.2) 405 (73.0) 211 (79.6)
 ≥ 65 y 246 (24.5) 42 (22.8) 150 (27.0) 54 (20.4)
Sex, n (%) (n = 1004) (n = 184) (n = 555) (n = 265)
 Male 600 (59.8) 117 (63.6) 335 (60.4) 148 (55.8)
 Female 404 (40.2) 67 (36.4) 220 (39.6) 117 (44.2)
Race, n (%) (n = 1004) (n = 184) (n = 555) (n = 265)
 White 971 (96.7) 167 (90.8) 539 (97.1) 265 (100.0)
 Nonwhite 33 (3.3) 17 (9.2) 16 (2.9) 0
Region, n (%) (n = 1004) (n = 184) (n = 555) (n = 265)
 North America 270 (26.9) 47 (25.5) 163 (29.4) 60 (22.6)
 Europe 590 (58.8) 108 (58.7) 314 (56.6) 168 (63.4)
 Australia/New Zealand/Others 144 (14.3) 29 (15.8) 78 (14.1) 37 (14.0)
Baseline disease stage, n (%) (n = 1004) (n = 184) (n = 555) (n = 265)
 Unresectable IIIC, M1a, or M1b 332 (33.1) 57 (31.0) 184 (33.2) 91 (34.3)
 M1c 672 (66.9) 127 (69.0) 371 (66.8) 174 (65.7)
Baseline ECOG PS, n (%) (n = 1001) (n = 182) (n = 554) (n = 265)
 0 651 (65.0) 129 (70.9) 343 (61.9) 179 (67.5)
 1 350 (35.0) 53 (29.1) 211 (38.1) 86 (32.5)
Baseline LDH, n (%) (n = 942) (n = 173) (n = 523) (n = 246)
 Normal 495 (52.5) 82 (47.4) 276 (52.8) 137 (55.7)
 Elevated ≤ 2 × ULN 290 (30.8) 61 (35.3) 154 (29.4) 75 (30.5)
 Elevated > 2 × ULN 157 (16.7) 30 (17.3) 93 (17.8) 34 (13.8)
Baseline liver metastasis, n (%) (n = 1001) (n = 184) (n = 552) (n = 265)
 Yes 375 (35.7) 69 (37.5) 199 (36.1) 89 (33.6)
 No 644 (64.3) 115 (62.5) 353 (63.9) 176 (66.4)
ECOG PS at PD, n (%) (n = 926) (n = 166) (n = 519) (n = 241)
 0 489 (52.8) 108 (65.1) 266 (51.3) 115 (47.7)
 1 356 (38.4) 50 (30.1) 209 (40.3) 97 (40.2)
 2 55 (5.9) 4 (2.4) 29 (5.6) 22 (9.1)
 3 22 (2.4) 4 (2.4) 13 (2.5) 5 (2.1)
 4 4 (0.4) 0 2 (0.4) 2 (0.8)
Postprogression treatment, n (%) (n = 1004) (n = 184) (n = 555) (n = 265)
 Immunotherapy 202 (20.1) 39 (21.2) 114 (20.5) 49 (18.5)
 Targeted therapy 58 (5.8) 14 (7.6) 27 (4.9) 17 (6.4)
 Other 744 (74.1) 131 (71.2) 414 (74.6) 199 (75.1)
Baseline SLD, mm (n = 995) (n = 184) (n = 546) (n = 265)
 Mean (SD) 87.1 (75.2) 86.2 (63.7) 91.2 (85.6) 79.3 (57.2)
 Median (range) 70.0 (9–1310) 72.0 (10–398) 71.5 (9–1310) 66.0 (9–295)
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monotherapy cohort, and 24.4% (95% CI 7.8–41.1) in 
the dacarbazine cohort. Among patients with base-
line LDH elevations > 2 × ULN (the least favorable sub-
group), 3-year ppOS rates were not estimable (NE; 95% 
CI NE–NE) in the cobimetinib plus vemurafenib cohort, 
2.5% (95% CI 0.0–5.8) in the vemurafenib monotherapy 
cohort, and NE (95% CI NE–NE) in the dacarbazine 
cohort.
Across treatment cohorts, patients who received 
immunotherapy or targeted therapy as initial treatment 
after progression had better survival outcomes than 
those given other treatments, even among those with 
LDH elevations.
Impact of Initial ppRx on ppOS
Among 1027 patients with PD at the time of data cutoff, 
218 received initial ppRx with immunotherapy and 82 
received targeted therapy (Additional file  1: Table  S2). 
Median ppOS was 10.4  months (95% CI 8.1–11.8) in 
patients who received initial ppRx with immunotherapy 
and 15.9  months (95% CI 12.2–18.9) in those who 
received targeted therapy (Fig. 3). ppOS rates at 3 years 
were 21.1% (95% CI 15.5–26.7) and 25.4% (95% CI 15.0–
35.9), respectively.
ppRx patterns
Among patients who received initial ppRx with immu-
notherapy, initial treatment was ipilimumab in most 
patients (200 of 218 patients; 91.7%) (Additional file  1: 
Table  S2); subsequent treatment frequently comprised 
anti–PD-1 therapy or BRAF and/or MEK inhibition 
(Fig. 4; Additional file 1: Table S3). Among patients who 
received initial ppRx with targeted therapy, initial treat-
ment was most commonly single-agent BRAFi (61 of 82 
patients [74.4%]; Additional file  1: Table  S2); targeted 
therapy was frequently followed by anti–PD-1 or anti–
cytotoxic T-lymphocyte–associated protein 4 (CTLA-
4) therapy (Fig.  4; Additional file  1: Table  S3). Among 
patients who received other initial ppRx, 220 received 
chemotherapy and 507 received no treatment (Additional 
file  1: Table  S2). Among the 220 patients who received 
809 patients 
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Fig. 1 Recursive partitioning analysis for prognostic subgroups in all pooled patients. Recursive partitioning decision tree and ppOS outcomes 
by identified prognostic subgroups for all pooled patients. Data are presented as percentage (95% CI). ECOG PS Eastern Cooperative Oncology 
Group performance status, IT immunotherapy, LDH lactate dehydrogenase, PD progressive disease, ppOS postprogression overall survival, ppRx 
postprogression treatment, TT targeted therapy, ULN upper limit of normal
(See figure on next page.)
Fig. 2 Postprogression overall survival by treatment cohort. Kaplan–Meier curves of ppOS in a cobimetinib plus vemurafenib cohort, b 
vemurafenib monotherapy cohort, and c dacarbazine cohort. CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance 
status, IT immunotherapy, LDH lactate dehydrogenase, NE not estimable, PD progressive disease, ppOS postprogression overall survival, ppRx initial 
postprogression treatment, TT targeted therapy, ULN upper limit of normal
Page 6 of 12Ascierto et al. J Transl Med          (2020) 18:294 
0
0
20
40
60
80
100
pp
O
S 
(%
)
No. at risk
Normal LDH + stage IIIC/M1a/M1b
Normal LDH + stage M1c + ppRx IT/TT
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0
Normal LDH + stage M1c + ppRx other + ECOG PS at PD >0
Elevated LDH (≤2 × ULN) + ppRx IT/TT
Elevated LDH (≤2 × ULN) + ppRx other
Elevated LDH (>2 × ULN)
Normal LDH + stage IIIC/M1a/M1b
Normal LDH + stage M1c + ppRx IT/TT
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0
Normal LDH + stage M1c + ppRx other + ECOG PS at PD >0
Elevated LDH (≤2 × ULN) + ppRx IT/TT
Elevated LDH (≤2 × ULN) + ppRx other
Elevated LDH (>2 × ULN)
Censored+
13.3 (10.2–17.5)
Median ppOS (95% CI)
11.8 (8.5–18.4)
8.0 (5.8–14.1)
3.0 (1.6–8.3)
6.6 (4.3–15.3)
4.0 (3.0–5.4)
1.8 (1.1–3.3)
5
Time (months)
10 15 20 25 30 35 40 45 50
70 53 41 31 24 18 15 13 12
27 21 16 10 6 6 6 6 6 3
1
7
2
1
1
4
15 12 6
5 4 2
3 1 1
2 2
1 1
2
1
121 7
18 11 6 6 4 4 3 2 2
57 24 12 7 5
1
3 1
34 7 2 1
55 60 65 70
+
+
+
+ + +++ + ++++
+
++
+++
+
+
+ + +
b
0
0
20
40
60
80
100
pp
O
S 
(%
)
No. at risk
No. at risk
Normal LDH + stage IIIC/M1a/M1b
Normal LDH + stage M1c + ppRx IT/TT
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0
Normal LDH + stage M1c + ppRx other + ECOG PS at PD >0
Elevated LDH (≤2 × ULN) + ppRx IT/TT
Elevated LDH (≤2 × ULN) + ppRx other
Elevated LDH (>2 × ULN)
Normal LDH + stage IIIC/M1a/M1b
Normal LDH + stage M1c + ppRx IT/TT
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0
Normal LDH + stage M1c + ppRx other + ECOG PS at PD >0
Elevated LDH (≤2 × ULN) + ppRx IT/TT
Elevated LDH (≤2 × ULN) + ppRx other
Elevated LDH (>2 × ULN)
Censored+
10.6 (7.1–14.9)
Median ppOS (95% CI)
12.4 (10.3–18.4)
7.7 (5.5–13.2)
4.1 (3.2–6.2)
9.6 (7.0–17.2)
4.1 (2.9–4.9)
2.4 (1.8–3.0)
5
Time (months)
10 15 20 25 30 35 40 45 50
129 84 61 42 28 22 17 14 9
50 38 32 22 15 13 11 9 5 2
1
1
53 35 21
11 6 2
12 10 4
2 2
3 2
2
2
145 19
42 28 19 15 10 6 4 1
1
1
113 42 18 8 6
4
3
1
2
1
2
193 21 7 4
55 60 65 70
+
+++++++++++++++
+++
+++
+
++++ +
+++ + + + + +
+
+ +
+ ++++
+
+
+
+
0
0
20
40
60
80
100
pp
O
S 
(%
)
a
Normal LDH + stage IIIC/M1a/M1b
Normal LDH + stage M1c + ppRx IT/TT
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0
Normal LDH + stage M1c + ppRx other + ECOG PS at PD >0
Elevated LDH (≤2 × ULN) + ppRx IT/TT
Elevated LDH (≤2 × ULN) + ppRx other
Elevated LDH (>2 × ULN)
Normal LDH + stage IIIC/M1a/M1b
Normal LDH + stage M1c + ppRx IT/TT
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0
Normal LDH + stage M1c + ppRx other + ECOG PS at PD >0
Elevated LDH (≤2 × ULN) + ppRx IT/TT
Elevated LDH (≤2 × ULN) + ppRx other
Elevated LDH (>2 × ULN)
Censored+
10.5 (5.8–18.2)
Median ppOS (95% CI)
14.4 (6.9–33.1)
8.5 (3.2–21.4)
3.2 (1.2–5.4)
9.2 (3.4–17.1)
5.5 (4.1–11.9)
2.4 (1.5–3.6)
5
Time (months)
10 15 20 25 30 35 40 45 50
41 28 17 13 10 7 7 5 3
21 15 10 8 6 6 3 2 1 1
19 10 7 6 4 2 1 1 1
11 3
19 12 8 6 3 3 2 2 1
44 22 14 7 4 2 2 1
33 6 4 2
55 60 65 70
c
Page 7 of 12Ascierto et al. J Transl Med          (2020) 18:294  
Ta
bl
e 
2 
Po
st
pr
og
re
ss
io
n 
ov
er
al
l s
ur
vi
va
l a
m
on
g 
al
l p
oo
le
d 
pa
ti
en
ts
 a
nd
 b
y 
tr
ea
tm
en
t c
oh
or
t a
cc
or
di
ng
 to
 p
ro
gn
os
ti
c 
su
bg
ro
up
CI
 c
on
fid
en
ce
 in
te
rv
al
, E
CO
G
 P
S 
Ea
st
er
n 
Co
op
er
at
iv
e 
O
nc
ol
og
y 
G
ro
up
 p
er
fo
rm
an
ce
 s
ta
tu
s, 
IT
 im
m
un
ot
he
ra
py
, L
D
H
 la
ct
at
e 
de
hy
dr
og
en
as
e,
 N
E 
no
t e
st
im
ab
le
, P
D
 p
ro
gr
es
si
ve
 d
is
ea
se
, p
pO
S 
po
st
pr
og
re
ss
io
n 
ov
er
al
l s
ur
vi
va
l, 
pp
Rx
 p
os
tp
ro
gr
es
si
on
 tr
ea
tm
en
t, 
TT
 ta
rg
et
ed
 th
er
ap
y,
 U
LN
 u
pp
er
 li
m
it 
of
 n
or
m
al
Pr
og
no
st
ic
 
su
bg
ro
up
A
ll 
pa
tie
nt
s
Co
bi
m
et
in
ib
 + 
ve
m
ur
af
en
ib
Ve
m
ur
af
en
ib
 m
on
ot
he
ra
py
D
ac
ar
ba
zi
ne
N
 (e
ve
nt
s)
pp
O
S,
 
m
ed
ia
n,
 m
o 
(9
5%
 C
I)
3-
ye
ar
 
pp
O
S,
  %
 
(9
5%
 C
I)
N
 (e
ve
nt
s)
pp
O
S,
 
m
ed
ia
n,
 m
o 
(9
5%
 C
I),
3-
ye
ar
 
pp
O
S,
  %
 
(9
5%
 C
I)
N
 (e
ve
nt
s)
pp
O
S,
 
m
ed
ia
n,
 m
o 
(9
5%
 C
I)
3-
ye
ar
 
pp
O
S,
  %
 
(9
5%
 C
I)
N
 (e
ve
nt
s)
pp
O
S,
 
m
ed
ia
n,
 m
o 
(9
5%
 C
I)
3-
ye
ar
 
pp
O
S,
  %
 
(9
5%
 C
I)
N
or
m
al
 L
D
H
 +
 st
ag
e 
III
C
/M
1a
/M
1b
24
0 
(1
70
)
11
.2
(9
.7
–1
4.
0)
23
.1
(1
7.
3–
28
.9
)
41
 (2
8)
10
.5
(5
.8
–1
8.
2)
23
.1
(8
.8
–3
7.
5)
12
9 
(8
8)
10
.6
(7
.1
–1
4.
9)
23
.8
(1
5.
5–
32
.1
)
70
 (5
4)
13
.3
(1
0.
2–
17
.5
)
22
.8
(1
2.
6–
32
.9
)
N
or
m
al
 L
D
H
 +
 st
ag
e 
M
1c
 +
 p
pR
x 
IT
/T
T
98
 (7
4)
12
.2
(1
0.
3–
16
.1
)
23
.4
(1
4.
5–
32
.3
)
21
 (1
4)
14
.4
(6
.9
–3
3.
1)
21
.7
(0
.0
–4
4.
2)
50
 (3
9)
12
.4
(1
0.
3–
18
.4
)
22
.3
(1
0.
3–
34
.3
)
27
 (2
1)
11
.8
(8
.5
–1
8.
4)
24
.4
(7
.8
–4
1.
1)
N
or
m
al
 L
D
H
 +
 st
ag
e 
M
1c
 +
 p
pR
x 
ot
he
r +
 E
CO
G
 P
S 
at
 P
D
 0
87
 (7
2)
8.
2
(6
.0
–1
0.
6)
6.
8
(0
.7
–1
3.
0)
19
 (1
3)
8.
5
(3
.2
–2
1.
4)
8.
6 
 
(0
.0
–2
4.
4)
53
 (4
5)
7.
7
(5
.5
–1
3.
2)
6.
0
(0
.0
–1
3.
6)
15
 (1
4)
8.
1
(5
.8
–1
4.
1)
6.
7
(0
.0
–1
9.
3)
N
or
m
al
 L
D
H
 +
 st
ag
e 
M
1c
 +
 p
pR
x 
ot
he
r +
 E
CO
G
 P
S 
at
 
PD
 >
 0
77
 (7
1)
3.
6
(2
.6
–4
.6
)
4.
5
(0
.0
–9
.4
)
11
 (1
0)
3.
2
(1
.3
–5
.4
)
0.
0
(0
.0
–0
.0
)
45
 (4
1)
4.
1
(3
.2
–6
.2
)
5.
7
(0
.0
–1
3.
0)
21
 (2
0)
3.
0
(1
.6
–8
.3
)
4.
8
(0
.0
–1
3.
9)
El
ev
at
ed
 L
D
H
 
(≤
 2
 ×
 U
LN
) +
 p
pR
x 
IT
/T
T
79
 (6
7)
8.
1
(6
.7
–1
2.
9)
11
.4
(3
.7
–1
9.
2)
19
 (1
7)
9.
2
(3
.4
–1
7.
1)
10
.5
(0
.0
–2
4.
3)
42
 (3
4)
9.
6
(7
.0
–1
7.
2)
14
.1
(2
.8
–2
5.
5)
18
 (1
6)
6.
6
(4
.3
–1
5.
3)
11
.1
(0
.0
–2
5.
6)
El
ev
at
ed
 L
D
H
 
(≤
 2
 ×
 U
LN
) +
 p
pR
x 
ot
he
r
21
4 
(1
86
)
4.
2
(3
.5
–5
.0
)
5.
0
(1
.1
–8
.8
)
44
 (3
5)
5.
5
(4
.1
–1
1.
9)
8.
4
(0
.0
–1
8.
9)
11
3 
(9
5)
4.
1
(2
.9
–4
.9
)
8.
6
(2
.8
–1
4.
3)
57
 (5
6)
4.
0
(3
.0
–5
.4
)
0.
0
(0
.0
–0
.0
)
El
ev
at
ed
 L
D
H
 
(>
 2
 ×
 U
LN
)
16
0 
(1
50
)
2.
3
(1
.8
–2
.7
)
2.
7
(0
.0
–5
.5
)
33
 (2
9)
2.
4
(1
.5
–3
.6
)
N
E
(N
E–
N
E)
93
 (8
9)
2.
4
(1
.8
–3
.0
)
2.
5
(0
.0
–5
.8
)
34
 (3
2)
1.
8
(1
.2
–3
.3
)
N
E
(N
E–
N
E)
Page 8 of 12Ascierto et al. J Transl Med          (2020) 18:294 
initial ppRx with chemotherapy, subsequent treatment 
was most commonly chemotherapy or anti–CTLA-4 
therapy (Fig. 4; Additional file 1: Table S3).
Among patients with evidence of additional treat-
ment, median time to next treatment (time from start 
of initial ppRx to start of next line of ppRx or death) was 
4.4  months (95% CI 4.0–4.9) in patients who received 
initial ppRx with immunotherapy, 6.0  months (95% CI 
4.3–7.6) in those who received targeted therapy, and 
3.8  months (95% CI 3.3–4.3) in those who received 
chemotherapy.
Discussion
In this exploratory analysis of data pooled from four key 
trials of vemurafenib or cobimetinib plus vemurafenib, 
a combination of baseline LDH and disease stage, initial 
ppRx, and ECOG PS at PD were identified as key prog-
nostic factors for ppOS in patients with metastatic mel-
anoma. Original treatment regimen (cobimetinib plus 
vemurafenib, vemurafenib monotherapy, or dacarbazine) 
did not appear to impact survival outcomes associated 
with ppRx.
Previous analyses in patients with metastatic mela-
noma treated with BRAFi and/or MEKi have consistently 
identified baseline LDH, ECOG performance status, 
and extent of disease as prognostic factors for OS [15–
18]. In the current analysis, baseline LDH remained the 
most important prognostic factor for OS following pro-
gression. Among patients with normal baseline LDH, 
baseline disease stage and ECOG PS at the time of PD 
were also identified as key prognostic factors for ppOS. 
Additionally, initial ppRx was identified as a statisti-
cally significant independent prognostic factor for ppOS 
on both sides of the regression tree (among patients 
with normal baseline LDH and those with LDH eleva-
tions ≤ 2 × ULN). Interestingly, among patients with nor-
mal baseline LDH, patients with stage M1c disease who 
received initial ppRx with immunotherapy or targeted 
therapy were able to achieve ppOS that was at least as 
good as that obtained in patients with stage IIIC/M1a/
M1b disease.
Considerable debate exists regarding the optimal 
sequence of treatment with targeted therapies and 
immunotherapies for patients with BRAF-mutated 
metastatic melanoma. To date, only low-quality evi-
dence is available to inform treatment sequencing deci-
sions, but randomized studies are currently underway. 
Retrospective analyses, mostly involving ipilimumab, 
have suggested that prior treatment with a BRAFi is 
associated with an inferior response to subsequent 
immunotherapy [19–21], whereas recent analyses 
involving nivolumab and pembrolizumab are more 
controversial [22, 23, 25–27]. In the current analysis, 
patients who received initial ppRx with immunotherapy 
or targeted therapy had similar OS outcomes across the 
cobimetinib plus vemurafenib, vemurafenib monother-
apy, and dacarbazine cohorts. After adjusting for other 
covariates, ppRx with immunotherapy or targeted 
therapy was associated with longer ppOS than ppRx 
with other treatments regardless of original treatment 
assignment. Furthermore, observed ppOS outcomes in 
patients receiving initial ppRx with immunotherapy in 
0
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Fig. 3 Postprogression overall survival by initial postprogression treatment. Kaplan–Meier curves of ppOS in all pooled patients receiving initial 
postprogression treatment with immunotherapy or targeted therapy (n = 300). ppOS postprogression overall survival
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this study (92% ipilimumab) appeared to be compara-
ble to reported OS outcomes with ipilimumab in previ-
ously treated patients (median OS, 10.4 vs 10.7 months; 
3-year OS, 21% vs 20%) [12]. Taken together, these 
results suggest that clinically relevant responses can be 
achieved with immunotherapy following progression 
on targeted therapy. In addition, observation of longer 
ppOS among patients who received initial ppRx with 
targeted therapy (74% single-agent BRAFi) compared 
with initial ppRx with treatments other than immuno-
therapy or targeted therapy is consistent with the find-
ings of recent studies suggesting that reinitiation of 
BRAFi and/or MEKi following PD can provide clinical 
benefit [29].
These findings introduce an additional layer of com-
plexity in the interpretation of treatment effects related 
to OS outcomes reported in randomized controlled tri-
als. It should be noted that a significant proportion of 
patients across treatment cohorts received multiple lines 
of ppRx. Among patients who received ppRx with immu-
notherapy, more than 90% received ipilimumab as their 
initial ppRx, whereas anti–PD-1 therapy was predomi-
nantly used after failure of initial ppRx. Results from a 
recent study, albeit in the treatment-naive setting, sug-
gest more favorable outcomes with anti–PD-1 followed 
by ipilimumab compared with the reverse sequence [30]. 
Proper interpretation of OS outcomes will require con-
sideration of patient and disease characteristics as well as 
the distribution and sequence of treatments received fol-
lowing progression.
Strengths of this pooled analysis include the large 
number of patients from studies conducted in similar 
populations, sufficient follow-up for robust survival anal-
yses, and prospective data collection using standardized 
schedules and methods. Further, the current analysis is 
largely based on data from randomized studies, wherein 
patients with similar baseline prognostic factors received 
a reference first-line and experimental treatment; this 
analysis is, therefore, less subject to the bias inherent in 
retrospective analyses of postprogression survival using 
data from patients treated in routine clinical practice 
where treatment decisions were based on physician and 
individual patient preferences [19–22]. However, as a ret-
rospective exploratory analysis our analysis is also sub-
ject to limitations. The pooled dataset included patients 
enrolled in nonrandomized studies and original treat-
ment assignment may be subject to selection bias. Also, 
choice of ppRx was not randomized or dictated by study 
protocols and may have been influenced in a nonuniform 
manner by changes in access to new treatments across 
the approximate 8-year time period over which the 
included studies were conducted.
Conclusions
LDH, extent of disease, and ECOG PS remain sig-
nificant prognostic factors following progression after 
treatment with cobimetinib plus vemurafenib, vemu-
rafenib monotherapy, or dacarbazine in patients with 
BRAFV600-mutated metastatic melanoma. ppRx was 
also identified as an additional independent prognos-
tic factor for OS following progression. Patients who 
progress following treatment with BRAFi and/or MEKi 
derive an OS benefit from subsequent treatment with 
immunotherapy or additional targeted therapy.
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